Resources for Your Patients

IncyteCARES is committed to providing resources for your patients taking Jakafi® (ruxolitinib) for intermediate and high-risk myelofibrosis or patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.

After you prescribe Jakafi to appropriate patients and enroll them in IncyteCARES, available patient benefits include:

  • Ongoing educational materials and resources mailed to patients to supplement information they have received from your office regarding therapy with Jakafi
  • Tools to help patients work with you and take a more active role in their care
  • Access to a dedicated IncyteCARES registered nurse who works one-on-one with patients and caregivers as a single point of contact for the program
  • Referrals to independent nonprofit organizations (INOs) or foundations* for additional support beyond what IncyteCARES can provide. Referral organizations may be able to assist with:
    • Arranging transportation to and from medical appointments
    • Travel cost assistance for gas, tolls and tax, parking, and bus or train fare if needed
    • Copay/coinsurance assistance for government-insured patients
    • Emotional and educational support
    • Supportive counseling for emotional, social, and practical concerns
    • Information about support groups and referrals to local services at no cost

*Some foundations or organizations may receive or have received donations from Incyte Corporation.

IncyteCARES ongoing education and support

Starter Packet for your patients

We encourage you to provide your patients with an IncyteCARES Patient Starter Packet and recommend they enroll in the program to receive ongoing support and resources after you write their initial prescription for Jakafi.

The Starter Packet includes the following materials for your patient:

  • Getting Started With Jakafi brochure
  • Pharmacy card
  • IncyteCARES brochure
  • Information about financial assistance options

Patient Welcome Kit for your patients

As part of IncyteCARES, we offer other resources, including a Welcome Kit that is shipped at the same time as the initial prescription. The Welcome Kit includes:

  • Cover letter
  • Disease-specific educational brochure
  • Pill caddy

Continuing patient education and support materials

IncyteCARES also helps reinforce your patient education efforts by providing:

  • Ongoing educational information about the patient's condition and Jakafi
  • Reports to update you on any conversations between your patients and the IncyteCARES oncology certified nurse

Supporting materials

IncyteCARES enrollment form

To initiate patient enrollment, download and complete the form, then fax to the program at 1-855-525-7207.

Sample letter of medical necessity

Some payers require physicians to provide documentation of medical necessity for Jakafi. This sample letter is provided to assist you with fulfilling these requirements.

Sample letter of appeal

This sample letter is provided to assist you in appealing an initial denial for Jakafi.

IncyteCARES FAQs for HCPs

Answers to commonly asked questions about IncyteCARES.

Indications and Usage

Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.

Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.

Important Safety Information

  • Treatment with Jakafi® (ruxolitinib) can cause thrombocytopenia, anemia and neutropenia, which are each dose‐related effects. Perform a pre‐treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
  • Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
  • Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi
  • Severe neutropenia (ANC <0.5 × 109/L) was generally reversible by withholding Jakafi until recovery
  • Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly
  • Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk‐benefit determination
  • Progressive multifocal leukoencephalopathy (PML) has occurred with ruxolitinib treatment for myelofibrosis. If PML is suspected, stop Jakafi and evaluate
  • Advise patients about early signs and symptoms of herpes zoster and to seek early treatment
  • Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines
  • When discontinuing Jakafi, myeloproliferative neoplasm‐related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi‐organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation
  • Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations
  • Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia
  • The three most frequent non-hematologic adverse reactions (incidence >10%) were bruising, dizziness and headache
  • A dose modification is recommended when administering Jakafi with strong CYP3A4 inhibitors or fluconazole or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy
  • Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breast-feed

Please see Full Prescribing Information for Jakafi.